Menu
Boston, MA – January 22, 2024 — SOPHiA GENETICS announced today that it was honored by Built In on its 2024 Best Places To Work Awards. SOPHiA GENETICS was named on the Boston mid-size company and overall best places to work lists. The annual awards program includes companies of all sizes, from startups to those in the enterprise, and honors both remote-first employers as well as companies in large tech markets across the U.S.
“We are honored to be included once again in Built In’s Best Places to Work. We are proud of our company culture that makes us a standout amongst Boston companies. At SOPHiA GENETICS, we are not just a tech company: we are a team of passionate, driven individuals who are propelled forward in their work by a shared passion to make an impact on the world, looking to leave our legacy with the work we do.” said Manuela Valente, Chief People Officer, SOPHiA GENETICS.
Built In determines the winners of Best Places to Work based on an algorithm, using company data about compensation and benefits. To reflect the benefits candidates are searching for more frequently on Built In, the program also weighs criteria like remote and flexible work opportunities, programs for DEI and other people-first cultural offerings.
“I’d like to extend our heartfelt congratulations to the 2024 Best Places to Work winners,” says Maria Christopoulos Katris. “I am truly inspired by these companies that have risen to the challenge of fostering a positive work environment, maintaining a strong brand, and ensuring employee satisfaction. The future is filled with promise and we are so excited to see what lies ahead.”
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on X, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
ABOUT BUILT IN
Built In is creating the largest candidate generation platform for technology professionals globally. Monthly, millions of the industry’s most in-demand professionals visit the site from across the world. They rely on our platform to stay ahead of tech trends and news, learn skills to accelerate their careers and find opportunities at companies whose values they share. Built In also serves thousands of innovative companies from startups to the Fortune 500. By putting their stories in front of our uniquely engaged audience, we help them reach otherwise hard-to-hire tech professionals. www.builtin.com.
ABOUT BUILT IN’S BEST PLACES TO WORK
Built In’s annual Best Places to Work program honors companies with the best total rewards packages across the U.S. and in the following tech hubs: Atlanta, Austin, Boston, Chicago, Colorado, Dallas, Houston, Los Angeles, Miami, New York, San Diego, San Francisco, Seattle and Washington DC. Best Places to Work is distinct because its algorithm selects tech companies that build their offerings specifically around what tech professionals value in a workplace. Winners are announced in early January 2024. https://employers.builtin.com/best-places-to-work/
Media Contact:
Kelly Katapodis
[email protected]
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
